Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission

Sustained evidence from observational studies indicates that after remission of Cushing syndrome (CS) a cardiovascular risk phenotype persists. Here, we performed a translational study in active CS and CS in remission (RCS) to evaluate the subclinical cardiometabolic burden and to explore the direct pro‐inflammatory and prothrombotic potential of their sera on the endothelium in an in vitro translational atherothrombotic cell model.

[1]  K. Yamagishi,et al.  Soluble Vascular Cell Adhesion Molecule and Cardiovascular Disease: An Epidemiological View , 2017, Journal of atherosclerosis and thrombosis.

[2]  P. Ambrosino,et al.  Markers of atherosclerosis in patients with Cushing’s syndrome: a meta-analysis of literature studies , 2017, Annals of medicine.

[3]  X. Escoté,et al.  Zinc alpha-2 glycoprotein is overproduced in Cushing's syndrome. , 2017, Endocrinologia, diabetes y nutricion.

[4]  C. Simeoli,et al.  Cushing’s disease: the burden of illness , 2017, Endocrine.

[5]  I. López-Vílchez,et al.  Endothelial damage in major depression patients is modulated by SSRI treatment, as demonstrated by circulating biomarkers and an in vitro cell model , 2016, Translational psychiatry.

[6]  J. Newell-Price.  Pituitary gland: Mortality in Cushing disease , 2016, Nature Reviews Endocrinology.

[7]  A. Isidori,et al.  Complications of Cushing's syndrome: state of the art. , 2016, The lancet. Diabetes & endocrinology.

[8]  Niki Karavitaki,et al.  Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[9]  M. D. De Martino,et al.  Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. , 2016, Frontiers of hormone research.

[10]  M. Gadelha,et al.  Adverse effects of glucocorticoids: coagulopathy. , 2015, European journal of endocrinology.

[11]  M. Minnetti,et al.  Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. , 2015, European journal of endocrinology.

[12]  L. Nieman,et al.  Cushing's syndrome , 2015, The Lancet.

[13]  M. Díaz-Ricart,et al.  Role of sodium tungstate as a potential antiplatelet agent , 2015, Drug design, development and therapy.

[14]  M. Díaz-Ricart,et al.  TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia , 2015, European journal of clinical investigation.

[15]  M. Puig-Domingo,et al.  Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up , 2014, Pituitary.

[16]  E. Vicaut,et al.  Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011) , 2012, Cerebrovascular Diseases.

[17]  A. Klibanski,et al.  Adipokines and Cardiovascular Risk in Cushing’s Syndrome , 2011, Neuroendocrinology.

[18]  R. Gomis,et al.  Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responses , 2011, Journal of thrombosis and haemostasis : JTH.

[19]  I. Conget,et al.  Preclinical arterial disease in patients with type 1 diabetes without other major cardiovascular risk factors or micro-/ macrovascular disease , 2011, Diabetes & vascular disease research.

[20]  G. Arnaldi,et al.  Coagulopathy in Cushing’s Syndrome , 2010, Neuroendocrinology.

[21]  J. Moreno-Navarrete,et al.  Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. , 2009, The Journal of clinical endocrinology and metabolism.

[22]  V. Montori,et al.  WITHDRAWN: The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. , 2009, European journal of endocrinology.

[23]  M. Díaz-Ricart,et al.  The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  S. Cannavò,et al.  Soluble adhesion molecules levels in patients with Cushing’s syndrome before and after cure , 2008, Journal of endocrinological investigation.

[25]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[26]  W. Aird.  Endothelium in health and disease. , 2008, Pharmacological reports : PR.

[27]  Mireia Junyent,et al.  Ecografía carotídea en la evaluación de aterosclerosis preclínica. Distribución de valores del grosor íntima-media y frecuencia de placas de ateroma en una cohorte comunitaria española , 2005 .

[28]  Rosa Gilabert,et al.  [Carotid ultrasound in the assessment of preclinical atherosclerosis. Distribution of intima-media thickness values and plaque frequency in a Spanish community cohort]. , 2005, Medicina clinica.

[29]  A. Colao,et al.  The metabolic syndrome and cardiovascular risk in Cushing's syndrome. , 2005, Endocrinology and metabolism clinics of North America.

[30]  M. D. De Martino,et al.  Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. , 2003, The Journal of clinical endocrinology and metabolism.

[31]  C. McCollum,et al.  Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. , 2000, Thrombosis research.

[32]  P. Marzullo,et al.  Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. , 1999, The Journal of clinical endocrinology and metabolism.

[33]  C. Bode,et al.  Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[34]  D. Wink,et al.  Determination of nitric oxide using fluorescence spectroscopy. , 1996, Methods in enzymology.

[35]  A. D'avanzo,et al.  [Cushing's syndrome]. , 1994, Annali italiani di chirurgia.

[36]  J. Sixma,et al.  A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. , 1983, The Journal of laboratory and clinical medicine.

[37]  R. Muggli,et al.  Automated Microdensitometry and Protein Assays as Measures for Platelet Adhesion and Aggregation on Collagen Coated Slides Under Controlled flow Conditions , 1979, Thrombosis and Haemostasis.

[38]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.